Figure 2. Relationship Between Copay and Prescription Abandonment for Patients Approved for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) Therapy.

Proportion of patients who filled their prescription after approval by range of copay (black line with markers), and the number of patients whose out of pocket costs were in that range (gray bars). Copay reflects ultimate out of pocket costs after co-insurance, patient approval program use, and coupon use.